Stem cell therapy rescues child with marrow disease

Pluristem Therapeutics touted a single case this morning in which the Israeli company's ($PSTI) stem cell therapy provided a medical turnaround for a 7-year-old girl who was suffering from a bone marrow disorder. After an injection of Pluristem's therapy, doctors saw boosted red and white blood cell levels in the girl, whose condition involves a scarcity of blood-forming stem cells, Reuters reported. Pluristem's stock jumped on the news and traded up more than 16% to $2.72 as of 11:48 a.m. ET. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.